Low HDL Cholesterol

Condition: Low HDL Cholesterol  |  Category: Metabolic and Cardiovascular Health  |  Reviewed by: Brian Lamkin, DO

What Is Low HDL Cholesterol?

HDL (high-density lipoprotein) cholesterol functions as the body's reverse cholesterol transport system, removing cholesterol from arterial walls and transporting it back to the liver for recycling or excretion. Low HDL indicates that this protective clearance pathway is impaired, leaving cholesterol deposited in arterial walls where it contributes to atherosclerotic plaque formation. HDL also has anti-inflammatory, antioxidant, and endothelial-protective properties that extend beyond cholesterol transport.

The most common cause of low HDL in clinical practice is insulin resistance. Elevated insulin increases the activity of cholesterol ester transfer protein (CETP), which transfers triglycerides from VLDL particles into HDL particles. These triglyceride-enriched HDL particles become substrates for hepatic lipase, which rapidly clears them from the circulation. This is why low HDL and elevated triglycerides almost always appear together: they are both driven by the same insulin mechanism. The triglyceride-to-HDL ratio is one of the most clinically useful markers on a standard lipid panel because it captures this metabolic relationship in a single number.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Conventional lipidology notes low HDL as a risk factor and occasionally prescribes niacin or fibrates. Functional medicine identifies and treats the metabolic mechanisms that suppress HDL.

Insulin Resistance and CETP-Mediated HDL Clearance

This is the dominant mechanism. Elevated fasting insulin increases CETP activity, enriching HDL particles with triglycerides transferred from VLDL. These triglyceride-laden HDL particles are then rapidly degraded by hepatic lipase. The result: HDL levels fall as triglyceride levels rise, producing the inverse relationship that characterizes insulin-resistant dyslipidemia. HOMA-IR above 1.9 confirms the insulin resistance driving this process.

Chronic Inflammation and HDL Dysfunction

Systemic inflammation impairs HDL function independently of HDL levels. Inflammatory cytokines (TNF-alpha, IL-6) replace the anti-inflammatory enzyme paraoxonase-1 (PON-1) on HDL particles with serum amyloid A (SAA), converting protective HDL into dysfunctional or even pro-inflammatory HDL. Elevated hs-CRP identifies this inflammatory contribution. A patient with "adequate" HDL levels but elevated hs-CRP may have functionally impaired HDL that does not provide the expected cardiovascular protection.

Sedentary Lifestyle and Dietary Pattern

Physical inactivity reduces lipoprotein lipase activity, impairing the maturation of HDL particles from small, lipid-poor HDL3 to large, cholesterol-rich HDL2. Regular exercise (both aerobic and resistance) is one of the most consistent HDL-raising interventions. A high-carbohydrate, low-fat diet reduces HDL by restricting the phospholipid and cholesterol substrates needed for HDL particle synthesis while simultaneously increasing the insulin drive that accelerates HDL clearance.

Hormonal Decline and Thyroid Dysfunction

Testosterone, estrogen, and thyroid hormone all influence HDL metabolism. Testosterone deficiency in men and estrogen decline in postmenopausal women are associated with HDL reduction. Hypothyroidism impairs hepatic lipid metabolism and contributes to the dyslipidemia pattern. Hormonal evaluation is a component of comprehensive low-HDL assessment.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

Low HDL evaluation requires markers that identify the metabolic mechanism suppressing HDL, not just confirmation that HDL is low.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient on a statin with low HDL and elevated triglycerides: LDL at target on rosuvastatin. HDL 34, triglycerides 195. Told "LDL is great, the rest is genetic." Fasting insulin 17, HOMA-IR 3.9. The statin addressed LDL but the insulin-driven atherogenic dyslipidemia remained untreated. Carbohydrate reduction and time-restricted eating raised HDL to 52 and reduced triglycerides to 88 within 10 weeks.
• The patient told low HDL is genetic and unmodifiable: Family history of low HDL. Father had a heart attack at 54. Patient HDL 32, triglycerides 230. Told nothing can be done. Fasting insulin 21, HOMA-IR 5.0, visceral fat elevated on DEXA. Aggressive insulin sensitization raised HDL to 48 and reduced triglycerides to 110. The "genetic" HDL had a significant metabolic component that was never evaluated.
• The low-fat dieter with falling HDL: Adopted a very low-fat, high-carbohydrate diet for heart health. Total cholesterol dropped but HDL fell from 54 to 38 while triglycerides rose from 95 to 175. The carbohydrate increase drove insulin up, increasing CETP activity and HDL clearance while the fat restriction removed the substrate for HDL synthesis. Reintroducing adequate healthy fats and reducing carbohydrate reversed both trends.
• The metabolic syndrome patient with five medications: HDL 35, triglycerides 220, fasting glucose 108, blood pressure 142/88, waist circumference 42 inches. On statin, fibrate, metformin, lisinopril, and aspirin. Five medications treating five downstream markers of one upstream process: insulin resistance. Aggressive insulin sensitization through dietary modification, time-restricted eating, berberine, and resistance training improved all five markers, allowing reduction of three medications over 6 months.

Treatment and Optimization Strategy

Metabolic and Lifestyle HDL Restoration

The most effective HDL-raising interventions target the metabolic and lifestyle factors that suppress HDL rather than attempting to pharmacologically force HDL levels higher.

What Most Doctors Miss

• Low HDL and elevated triglycerides are the same disease expressed through two markers: they are both driven by insulin resistance through the CETP mechanism. Treating them as separate problems with separate medications misses the unifying cause.
• The triglyceride/HDL ratio is more important than either value alone: a ratio above 3.0 identifies insulin-resistant atherogenic dyslipidemia that standard LDL-focused management does not capture or treat.
• HDL function matters more than HDL level: inflammation converts HDL from protective to dysfunctional without changing the measured level. A patient with HDL 50 and hs-CRP 5.0 may have worse cardiovascular protection than a patient with HDL 40 and hs-CRP 0.5.
• Pharmacological HDL raising does not reduce cardiovascular events: niacin trials showed HDL increases without outcome benefit, demonstrating that raising HDL artificially without correcting the metabolic mechanism is insufficient. The intervention that works is metabolic correction that raises HDL as a downstream consequence.

When to Seek Medical Care

If your lipid panel shows HDL below 40 mg/dL (men) or 50 mg/dL (women), a triglyceride/HDL ratio above 2.0, or if you have low HDL alongside elevated triglycerides, abdominal obesity, or elevated fasting glucose, a comprehensive metabolic evaluation is warranted. This is especially important if your HDL has not responded to statins, fibrates, or generic lifestyle advice.

At The Lamkin Clinic, low HDL evaluation includes fasting insulin, HOMA-IR, triglyceride/HDL ratio, hs-CRP, HbA1c, and comprehensive metabolic assessment, reviewed as an integrated cardiovascular and metabolic profile targeting the insulin-driven mechanism suppressing HDL.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Low HDL

At The Lamkin Clinic, low HDL evaluation begins with the triglyceride/HDL ratio and fasting insulin as cornerstone metabolic markers, supported by HOMA-IR, hs-CRP, HbA1c, and comprehensive metabolic and hormonal assessment. Treatment targets the insulin-driven CETP mechanism: carbohydrate modification, time-restricted eating, resistance training, omega-3 supplementation, and insulin sensitization to raise HDL by correcting the metabolic environment that suppresses it.

Related Conditions

Related Symptoms